Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: Results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)

A. Conconi, G. Martinelli, A. Lopez-Guillermo, P. L. Zinzani, A. J M Ferreri, L. Rigacci, L. Devizzi, U. Vitolo, S. Luminari, F. Cavalli, E. Zucca

Research output: Contribution to journalArticle

Abstract

Background: The nuclear factor-kappa B activation in mucosa-associated lymphoid tissue (MALT) lymphoma pathogenesis provided the rationale for the evaluation of bortezomib in this malignancy. Patients and methods: Thirty-two patients with relapsed/refractory MALT lymphoma were enrolled. Thirty-one patients received bortezomib 1.3 mg/m2 i.v., on days 1, 4, 8, and 11, for up to six 21-day cycles. Results: Median age was 63 years (range, 37-82 years). Median number of prior therapies was 2 (range, 1-4). Nine patients had Ann Arbor stage I, 7 patients had stage II, and 16 patients had stage IV. Primary lymphoma localization was the stomach in 14 patients; multiple extranodal sites were present in 10 patients. Among the 29 patients assessable for response, the overall response rate was 48% [95% confidence interval (CI) 29% to 67%], with 9 complete and 5 partial responses. Nine patients experienced stable disease and six had disease progression during therapy. The most relevant adverse events were fatigue, thrombocytopenia, neutropenia, and peripheral neuropathy. After a median follow-up of 24 months, the median duration of response was not reached yet. Five deaths were reported, in two patients due to disease progression. Conclusion: Bortezomib is active in relapsed MALT lymphomas. Further investigations to identify optimal bortezomib dose, schedule, and combination regimens are needed since the frequent detection of dose-limiting peripheral neuropathy.

Original languageEnglish
Pages (from-to)689-695
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number3
DOIs
Publication statusPublished - Mar 2011

Keywords

  • Bortezomib
  • MALT lymphoma
  • Non-Hodgkin's lymphoma
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: Results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG)'. Together they form a unique fingerprint.

  • Cite this